Fu­sion and Cyteir re­fo­cus pipelines; Nona Bio­sciences col­lab­o­rat­ing with Phar­maEssen­tia

Sev­er­al biotechs are look­ing to make changes to their pipelines as the quar­ter has drawn to a close.

Mass­a­chu­setts-based Cyteir said Wednes­day it is go­ing to fo­cus on CYT-0851, which is de­signed to be used in com­bi­na­tion with capecitabine as a treat­ment for ad­vanced ovar­i­an can­cer. For its pre­clin­i­cal DNA poly­merase theta in­hibitor pro­gram, it plans to out-li­cense the pro­gram, the com­pa­ny an­nounced in its Q1 re­port.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.